Percutaneous injection of autologous bone marrow concentrate cells significantly reduces lumbar discogenic pain through 12 months.

摘要: Degenerative disc disease (DDD) induces chronic back pain with limited nonsurgical options. In this open label pilot study, 26 patients (median age 40 years; range 18-61) received autologous bone marrow concentrate (BMC) injections (13 one level, 13 two levels). Pretreatment Oswestry disability index (ODI) and visual analog scale (VAS) were performed to establish baseline scores (average 56.5 79.3, respectively), while magnetic resonance imaging was independently scored according the modified Pfirrmann scale. Approximately 1 ml of BMC analyzed for total nucleated cell (TNC) content, colony-forming unit-fibroblast (CFU-F) frequency, differentiation potential, phenotype characterization. The average ODI VAS reduced 22.8 29.2 at 3 months, 24.4 26.3 6 25.0 33.2 12 respectively (p ≤ .0001). Eight twenty improved by grade year. contained 121 × 10(6) TNC/ml 2,713 CFU-F/ml (synonymous mesenchymal stem cells). Although all subjects presented a substantial reduction in pain, receiving greater than 2,000 experienced significantly faster VAS. Subjects older years who fewer an 33.7% 29.1% other patients' 69.5% (ODI, p = .03) 70.6% (VAS, .01). This study provides evidence safety feasibility treatment DDD indicates effect concentration on discogenic reduction.